Maverick Capital
Maverick Capital is a global investment firm with offices in New York, San Francisco, London, Hong Kong, Philadelphia, and Dallas. The firm seeks to grow and preserve capital through long/short hedged equity strategies and has extended its reach by backing private companies that represent disruptive business models or technologies. In addition to its main investment activities, Maverick Capital operates Maverick Ventures, its venture arm, which supports entrepreneurs from seed to growth stages, with a focus on healthcare, software and deep technology. The team generally leads rounds, takes board seats, and collaborates with management to build successful enterprises.
Top Sectors
Top Regions
https://crunchbase.com/organization/***
https://linkedin.com/company/***
https://signal.nfx.com/firms/***
Past deals in Pennsylvania
Areteia Therapeutics
Series A in 2024
Areteia Therapeutics is a biotechnology company focused on developing oral therapies for eosinophilic asthma to improve disease control. The company was spun out of Knopp and is advancing an oral drug designed to inhibit eosinophil maturation, aiming to reduce inflammation and alleviate symptoms of severe asthma. Phase 2 data from its program indicated the oral candidate lowers blood eosinophil counts, a marker associated with better lung function. By pursuing an oral, non-injectable treatment option, Areteia seeks to offer a convenient alternative to injectable therapies and broaden access for asthma patients. The company’s work centers on targeting eosinophil-related pathways to enhance asthma management and patient quality of life.
Areteia Therapeutics
Series A in 2022
Areteia Therapeutics is a biotechnology company focused on developing oral therapies for eosinophilic asthma to improve disease control. The company was spun out of Knopp and is advancing an oral drug designed to inhibit eosinophil maturation, aiming to reduce inflammation and alleviate symptoms of severe asthma. Phase 2 data from its program indicated the oral candidate lowers blood eosinophil counts, a marker associated with better lung function. By pursuing an oral, non-injectable treatment option, Areteia seeks to offer a convenient alternative to injectable therapies and broaden access for asthma patients. The company’s work centers on targeting eosinophil-related pathways to enhance asthma management and patient quality of life.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.